Clinical Trials Browser

Withdrawn × Ovarian Neoplasms × Sarcoma × Clear all

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05905341 2023-11-08

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

Phase 1 Withdrawn

BreastGynecologicSarcomaThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Ovarian Neoplasms

NCT03933761 2021-08-10

PRECISE

Phase 2 Withdrawn

GynecologicSarcoma

Carcinosarcoma, Ovarian Neoplasms

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Phase 1/2 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT01386502 2017-07-02

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors

Phase 1 Withdrawn

BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Colonic Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma

Clinical Trials

SMMART Adaptive Clinical Treatment (ACT) Trial

Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.

PRECISE

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors